title: Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects.
abstract: The pharmacokinetics of dexamethasone (DEX) were studied in 9 drug-free melancholically depressed patients and 10 healthy control subjects matched by sex and age. Each subject received 1 mg of DEX administered orally and by the (i.v.) route at 11:00 PM and serial blood samples were collected over the next 17 hours until 4:00 PM. There were no significant differences between the diagnostic groups and DEX bioavailability, peak plasma level, time to maximum concentration, or in elimination half-life after oral administration. Bioavailability estimates indicated that DEX absorption was incomplete and variable mean = 61%, SD = 14) in controls as well as depressed patients. In both groups there was a wide interindividual variability in plasma DEX levels following both oral and i.v. routes of administration. This variability could not be reliably predicted by differences in age, sex, or weight between subjects. The factors that accounted for most the variability in 4:00 PM plasma DEX levels after oral administration were clearance, bioavailability, and time to reach maximum concentration. Plasma DEX levels were lower in 3 depressed nonsuppressors compared to 3 matched controls who suppressed. No single pharmacokinetic factor was shown to be responsible for the lower DEX levels in the depressed nonsuppressors. These results indicate that plasma DEX levels need to be measured in each individual during the DST procedure so that this information may be taken into consideration when interpreting DST results.
authors.affiliation: Department of Psychiatry, University of Sydney, Australia.
authors.forename: B T
authors.initials: BT
authors.lastname: O'Sullivan
authors.forename: D J
authors.initials: DJ
authors.lastname: Cutler
authors.forename: G E
authors.initials: GE
authors.lastname: Hunt
authors.forename: C
authors.initials: C
authors.lastname: Walters
authors.forename: G F
authors.initials: GF
authors.lastname: Johnson
authors.forename: I D
authors.initials: ID
authors.lastname: Caterson
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D018592:Cross-Over Studies; D003866:Depressive Disorder / Q000097:blood* / Q000175:diagnosis / Q000523:psychology; D003907:Dexamethasone / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D007206:Individuality; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008875:Middle Aged; D010555:Personality Inventory; D012016:Reference Values
chemical_list: D003907:Dexamethasone